Premium Tirzepatide for Sale | 40mg per Vial | ≥99% Purity | 48-Hour Delivery Across EU & UK

Tirzepatide (LY3298176): The First-In-Class GIP/GLP-1 Dual Agonist for Advanced Research

https://eupeptidelap.co.uk/ is proud to present Tirzepatide 40mg (R&D Only) , a premium research-grade dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured to the highest analytical standards. As a trusted peptide vendor uk and leading EU peptide supplier, we provide researchers across Europe with Tirzepatide for sale that delivers exceptional purity, consistency, and documented quality .

Tirzepatide (LY3298176) represents a revolutionary advancement in incretin-based therapeutics as the first-in-class dual GIP/GLP-1 receptor co-agonist . This 39-amino acid synthetic peptide is engineered to simultaneously activate both GIP and GLP-1 receptors, leveraging the complementary actions of these two incretin hormones to produce superior metabolic effects compared to selective GLP-1 receptor agonism alone . The peptide contains a C20 diacid moiety that confers resistance to dipeptidyl peptidase IV (DPP-IV) degradation, resulting in a prolonged half-life suitable for once-weekly administration in clinical settings .

The molecular formula of Tirzepatide is C₂₂₅H₃₄₈N₄₈O₆₈, with a molecular weight of 4813.45 Da . Its unique structural features include amino acid substitutions designed to balance affinity for both GIP and GLP-1 receptors, with binding studies showing approximately equal potency at GIP receptors and approximately five-fold weaker affinity at GLP-1 receptors compared to native hormones . This balanced dual agonism is hypothesized to underlie its enhanced efficacy in metabolic research models.

Tirzepatide binds to GIP receptors with affinity similar to native GIP, while maintaining clinically meaningful GLP-1 receptor activation . The GIP and GLP-1 receptors are distributed throughout the body, including pancreatic endocrine cells (α and β cells), brain regions involved in appetite regulation, heart, blood vessels, immune cells, intestines, and kidneys . GIP receptors are also abundantly expressed on adipocytes, contributing to the peptide’s effects on lipid metabolism and fat distribution .

For researchers seeking to buy peptide online EU for investigations into metabolic disorders, obesity, diabetes, cardiovascular health, or neuroprotection, eupeptidelap.co.uk offers this premium research compound with comprehensive documentation, including Certificates of Analysis and batch-specific purity data. Whether your laboratory is based in London, Berlin, Paris, or anywhere in the European Union, our guaranteed 48 hour delivery peptide service ensures your research continues without interruption.

The Scientific Foundation of Tirzepatide

Mechanism of Action: Dual GIP/GLP-1 Receptor Activation

Tirzepatide exerts its effects through simultaneous activation of both GIP and GLP-1 receptors, producing synergistic actions that exceed what either pathway might achieve alone .

GIP Receptor Activation: GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone secreted by K cells in the proximal small intestine in response to nutrient ingestion. Historically overlooked due to reduced β-cell responsiveness observed in type 2 diabetes, GIP has been re-evaluated following the clinical success of dual agonists like Tirzepatide . GIP receptors are expressed on pancreatic β cells (stimulating insulin secretion), adipocytes (promoting lipid storage and metabolism), and in the brain (influencing appetite regulation) .

GLP-1 Receptor Activation: GLP-1 (glucagon-like peptide-1) is secreted by L cells throughout the intestine and activates receptors on pancreatic β cells, resulting in glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and reduced appetite . GLP-1 receptor agonists are established therapies for type 2 diabetes and obesity due to their insulinotropic effects, weight reduction, and proven cardiovascular benefits .

Synergistic Actions: The combination of GIP and GLP-1 receptor activation produces effects that exceed those of selective GLP-1 receptor agonists alone . Tirzepatide improves glycemic control, reduces fasting and postprandial glucose levels, increases satiety and fullness, reduces overall appetite, and decreases body weight by reducing adipose tissue mass . The drug increases pancreatic β-cell sensitivity to glucose and enhances insulin secretion in both first and second phases in a glucose-dependent manner. At a 15 mg dose, Tirzepatide increased first-phase insulin secretion by 466% and second-phase by 302%, while also increasing whole-body insulin sensitivity by 63% .

Pharmacokinetic Properties: Due to the presence of the C20 diacid moiety, Tirzepatide is resistant to DPP-IV degradation, resulting in a long half-life of approximately 6 days and high affinity for albumin (99% bound) . Following subcutaneous administration, peak plasma concentrations are achieved within 8-72 hours, with steady-state levels reached after 4 weeks. Absolute bioavailability is approximately 80% . Elimination involves cleavage of the peptide skeleton by proteolytic enzymes, beta-oxidation of the C20 fatty acid, and amide hydrolysis, with metabolites excreted in urine and feces .

Key Research Applications

Metabolic and Obesity Research: Tirzepatide is extensively used in studies investigating body weight regulation, adipose tissue biology, and energy homeostasis. Clinical trials have demonstrated that Tirzepatide enables many individuals to achieve ≥20% weight loss, marking a new era in obesity treatment research . In the SURMOUNT program, participants who lost ≥35% of body weight experienced substantial improvements in cardiometabolic parameters . The relationship between weight loss and cardiometabolic improvements is largely linear, with steeper effects observed for systolic blood pressure. Notably, insulin sensitivity and glycemic control improve even with modest weight loss, while lipid improvements become more pronounced after >10% weight reduction .

Type 2 Diabetes Research: Tirzepatide has been extensively studied for its effects on glycemic control, insulin secretion, and insulin sensitivity. In clinical trials, the drug improves HbA1c and reduces fasting and postprandial glucose levels in patients with type 2 diabetes . A Phase 2 randomized placebo-controlled trial in adults with type 1 diabetes and obesity demonstrated that Tirzepatide was superior to placebo for weight loss over 12 weeks, with participants losing a mean of 10.3 kg (8.8% body weight) compared to 0.7 kg in the placebo group . The treatment also improved HbA1c (mean difference -0.4%) and reduced total daily insulin dose by 35.1% compared to placebo .

Cardiovascular Research: Tirzepatide demonstrates significant vasculoprotective and anti-atherosclerotic effects that extend beyond glycemic control . The drug stimulates the mobilization and function of endothelial progenitor cells, facilitating vascular repair and mitigating hyperglycemia-induced damage. It enhances endothelial nitric oxide synthase (eNOS) activity, reduces expression of endothelial activation molecules such as ICAM-1 and VCAM-1, promotes vasodilation, and reduces peripheral vascular resistance . Furthermore, Tirzepatide inhibits inflammation by suppressing pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 . By improving endothelial function, reducing inflammation, and lowering body weight, the drug reduces both systolic and diastolic blood pressure . Cardiovascular protective mechanisms also include improvements in lipid metabolism (decreasing total cholesterol, LDL-C, and triglycerides while increasing HDL-C), suppression of macrophage inflammation, decreased foam-cell formation, and stabilization of atherosclerotic plaques .

Lipid Metabolism Research: Tirzepatide improves lipid profiles through multiple mechanisms. Clinical studies demonstrate reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, with concurrent increases in high-density lipoprotein cholesterol (HDL-C) . These lipid-modifying effects, combined with the drug’s anti-inflammatory and endothelial-protective properties, contribute to its overall cardiovascular benefit profile.

Neuroprotection and Neurological Research: Emerging evidence suggests that Tirzepatide may have therapeutic potential in neurological disorders including Alzheimer’s and Parkinson’s diseases . By addressing multiple pathophysiological pathways including insulin resistance, inflammation, and oxidative stress, Tirzepatide presents unique opportunities for investigating neuroprotective strategies. GIP and GLP-1 receptors are expressed in brain regions including the hippocampus, which is associated with memory and learning .

Metabolic-Associated Fatty Liver Disease (MAFLD) Research: Tirzepatide is being investigated for its effects on hepatic steatosis and inflammation in metabolic-associated fatty liver disease and non-alcoholic steatohepatitis (NASH) . The drug’s dual actions on weight reduction, insulin sensitivity, and lipid metabolism make it particularly relevant for liver disease research.

Chronic Kidney Disease Research: The anti-inflammatory and vascular-protective effects of Tirzepatide have implications for chronic kidney disease research . By reducing systemic inflammation and improving endothelial function, the drug may help preserve renal function in metabolic disease models.

Sleep Apnea Research: The SURMOUNT-OSA study demonstrated that Tirzepatide results in clinically important improvements in obstructive sleep apnea, an obesity-related complication . This finding expands the potential research applications of Tirzepatide to sleep medicine and respiratory research.

Heart Failure Research: The SUMMIT study investigated Tirzepatide’s impact on heart failure with preserved ejection fraction (HFpEF), showing improvements in this cardiovascular condition . These findings support research into the drug’s effects on cardiac function and myocardial remodeling.

Quality Assurance: Setting the Standard for Research Compounds

Manufacturing Excellence

eupeptidelap.co.uk sources Tirzepatide from certified GMP facilities with rigorous quality control protocols:

HPLC Purity Analysis: ≥99% purity verified by high-performance liquid chromatography
Mass Spectrometry Verification: Molecular weight confirmation via LC-HRMS
Batch-Specific Certificates of Analysis: Complete documentation for each production run
Impurity Profiling: Comprehensive analysis under stress conditions to ensure stability and quality

Chemical and Product Specifications

Specification	Detail
Product Name	Tirzepatide (LY3298176) – R&D Only
CAS Number	2023788-19-2
Molecular Formula	C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight	4813.45 Da
Amino Acid Length	39 amino acids
Purity	≥99% (HPLC verified)
Form	Lyophilized powder
Storage (Powder)	-20°C: up to 3 years; 4°C: up to 2 years
Storage (In solvent)	-80°C: up to 6 months; -20°C: up to 1 month
Half-Life	~5 days
Bioavailability	~80%
Protein Binding	99% bound to albumin
Shipping	Ambient temperature with protective packaging
Intended Use	Research and laboratory use only
Documentation	Certificate of Analysis provided with each batch

Stability and Handling

Lyophilized Form: Tirzepatide is supplied as a lyophilized powder to ensure long-term stability and integrity. Prior to reconstitution, allow the vial and solvent to reach ambient laboratory temperature.

Storage Recommendations: Store lyophilized Tirzepatide at -20°C for long-term storage (up to 3 years) or at 4°C for short-term storage (up to 2 years) . Once reconstituted in solvent, store at -80°C for up to 6 months or at -20°C for up to 1 month. Aliquot into single-use portions to avoid repeated freeze-thaw cycles .

Reconstitution: Reconstitute using bacteriostatic water or another suitable solvent according to your research protocol. Gentle swirling—not shaking—is recommended to dissolve the powder completely.

Real-World Research Applications and Investigator Experiences

Weight Loss and Cardiometabolic Research

The SURMOUNT clinical trial program has provided extensive data on Tirzepatide’s effects on weight loss and cardiometabolic parameters. A post hoc analysis of data from adults with obesity (n=1,605) randomized to once-weekly Tirzepatide (5, 10, or 15 mg) or placebo in the SURMOUNT-1 trial demonstrated that participants who lost ≥35% of body weight experienced substantial improvements: systolic blood pressure decreased by 14.2 mm Hg, diastolic blood pressure by 9.2 mm Hg, waist circumference by 32.4 cm, HOMA-IR by 59.7%, and HbA1c by 0.65 percentage points . The relationship between weight loss and cardiometabolic improvements was largely linear, with steeper effects for systolic blood pressure. Notably, insulin sensitivity and glycemic control improved even with modest weight loss, while lipid improvements were more pronounced after >10% weight reduction .

Type 1 Diabetes Research

The TIRTLE1 trial, a 12-week phase 2 double-blind randomized placebo-controlled study in adults with type 1 diabetes and BMI >30 kg/m², demonstrated that Tirzepatide was superior to placebo for weight loss. The mean change in weight was -10.3 kg (95% CI -12.8 to -7.7 kg) in the tirzepatide group and -0.7 kg (95% CI -1.4 to 2.8 kg) in the placebo group, representing 8.8% weight loss . In the tirzepatide group, 100% and 45% of participants experienced weight loss of ≥5% and ≥10% respectively, compared with 9% and 0% in the placebo group. Tirzepatide improved HbA1c (mean difference -0.4% vs. placebo; P = 0.05) and reduced total daily insulin dose (-24.2 units/day tirzepatide vs. -0.3 units/day placebo; difference from baseline vs. placebo -35.1%) .

Cardiovascular Protection Studies

Research has elucidated the multiple mechanisms underlying Tirzepatide’s cardiovascular protective effects. The drug stimulates mobilization and function of endothelial progenitor cells, facilitating vascular repair and mitigating hyperglycemia-induced damage. It enhances eNOS activity, reduces endothelial activation molecules (ICAM-1, VCAM-1), promotes vasodilation, and reduces peripheral vascular resistance . Tirzepatide inhibits inflammation by suppressing pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 . By improving endothelial function, reducing inflammation, and lowering body weight, Tirzepatide reduces both systolic and diastolic blood pressure .

Molecular Dynamics and Binding Studies

Recent research utilizing molecular dynamics simulations has provided detailed insights into Tirzepatide’s activation mechanism of GLP-1R and GIPR . Analysis of the dynamic conformational changes during receptor activation reveals a closure-open transition in the extracellular domain (ECD) and movement trends of the transmembrane helices, indicating similarities to the activation mechanism of class A GPCRs . The conserved residues contribute similarly toward binding to both GLP-1R and GIPR. Mutations in non-conserved residues in Tirzepatide affect binding affinity, with C-terminal mutations weakening binding affinity toward GLP-1R, while N-terminal mutations enhance affinity to GIPR, resulting in a biased binding mode.

Key Benefits

Premium Quality Manufacturing: GMP-certified production with rigorous quality control, ≥99% HPLC-verified purity
First-In-Class Dual Agonist: Simultaneous GIP and GLP-1 receptor activation for synergistic research applications
High Concentration: 40mg per vial—substantial quantity for extended research studies
Superior Metabolic Effects: Produces greater glycemic control and weight loss compared to selective GLP-1 receptor agonists
Weight Loss Research: Enables investigation of ≥20% body weight reduction in obesity models
Cardiovascular Protection: Multiple mechanisms including eNOS activation, endothelial repair, and anti-inflammatory effects
Anti-Atherosclerotic Effects: Reduces vascular inflammation, foam-cell formation, and stabilizes atherosclerotic plaques
Lipid Profile Improvement: Decreases total cholesterol, LDL-C, and triglycerides while increasing HDL-C
Blood Pressure Reduction: Reduces both systolic and diastolic blood pressure
Insulin Sensitivity Enhancement: Increases whole-body insulin sensitivity by 63% at therapeutic doses
β-Cell Function Research: Enhances both first and second-phase insulin secretion
Neuroprotection Studies: Emerging applications in Alzheimer’s and Parkinson’s disease research
MAFLD/NASH Research: Investigate effects on hepatic steatosis and inflammation
Sleep Apnea Research: Demonstrated improvements in obstructive sleep apnea
Heart Failure Research: Potential applications in HFpEF models
Extended Half-Life: C20 diacid confers DPP-IV resistance and prolonged duration
Comprehensive Documentation: Certificates of Analysis with batch-specific purity data
48-Hour EU & UK Delivery: Rapid shipping to research facilities across Europe
Batch Consistency: Rigorous quality control ensures lot-to-lot reproducibility
Expert Technical Support: Knowledgeable staff for reconstitution and protocol guidance
EU Sourced: Manufactured and distributed from within the European Union

Frequently Asked Questions

Q: Is Tirzepatide suitable for human consumption?

A: No. Tirzepatide 40mg (R&D Only) from eupeptidelap.co.uk is strictly for research and laboratory use only. It is not for human or animal consumption, and must not be used for therapeutic, diagnostic, or clinical applications. While Tirzepatide is approved by regulatory bodies including the FDA and EMA for the treatment of type 2 diabetes and obesity, research-grade material is intended for investigational purposes only . Researchers must handle this compound in accordance with institutional safety guidelines and local regulations.

Q: What purity level can I expect when I buy Tirzepatide from eupeptidelap.co.uk?

A: All Tirzepatide from eupeptidelap.co.uk is tested to ≥99% purity by HPLC . Each batch is individually analyzed, and Certificates of Analysis are provided with every order, ensuring you receive material suitable for rigorous research applications.

Q: How should I store Tirzepatide for long-term stability?

A: Store lyophilized Tirzepatide at -20°C for long-term storage (up to 3 years) or at 4°C for short-term storage (up to 2 years) . Protect from light and moisture. After reconstitution, aliquot into single-use portions and store at -80°C for up to 6 months or at -20°C for up to 1 month. Avoid repeated freeze-thaw cycles .

Q: What is the molecular weight and formula of Tirzepatide?

A: Tirzepatide has the molecular formula C₂₂₅H₃₄₈N₄₈O₆₈ and a molecular weight of 4813.45 Da . It is a 39-amino acid peptide containing a C20 diacid moiety that confers resistance to DPP-IV degradation .

Q: What is the mechanism of action of Tirzepatide?

A: Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that simultaneously activates both incretin hormone receptors . This dual agonism produces synergistic effects on glycemic control, insulin secretion, appetite suppression, and weight loss that exceed those of selective GLP-1 receptor agonists alone . The drug also exerts vasculoprotective effects through eNOS activation, endothelial repair, and anti-inflammatory mechanisms .

Q: What research areas commonly use Tirzepatide?

A: Tirzepatide is widely used in obesity and metabolic research , type 2 diabetes research , type 1 diabetes research , cardiovascular research , lipid metabolism studies , neuroprotection research , MAFLD/NASH research , sleep apnea research , heart failure research , and molecular pharmacology studies .

Q: Do you ship Tirzepatide to EU countries?

A: Yes. As a dedicated EU peptide supplier, we ship Tirzepatide to all European Union member states with our guaranteed 48 hour delivery peptide service. Our EU fulfilment centre ensures rapid delivery without customs delays. All shipments use protective packaging to maintain compound integrity during transit.

Q: What documentation do you provide with Tirzepatide orders?

A: Every order includes a Certificate of Analysis with batch-specific purity data. Additional documentation, including HPLC chromatograms and mass spectrometry data, is available upon request for researchers requiring comprehensive analytical verification.

Q: What is the half-life of Tirzepatide?

A: Tirzepatide has a long half-life of approximately 5 days, attributed to the C20 diacid moiety that confers resistance to DPP-IV degradation and high affinity for albumin (99% bound) .

Q: How does Tirzepatide compare to selective GLP-1 receptor agonists?

A: Tirzepatide provides superior glycemic control and weight loss compared with selective GLP-1 receptor agonists in clinical trials, demonstrating synergistic actions between the two incretin pathways . The dual agonism approach leverages complementary mechanisms to produce enhanced metabolic effects.

Q: Does Tirzepatide have cardiovascular protective effects?

A: Yes. Tirzepatide demonstrates significant vasculoprotective and anti-atherosclerotic effects beyond glycemic control, including stimulation of endothelial progenitor cells, enhanced eNOS activity, reduced endothelial activation molecules, anti-inflammatory effects, improved lipid profiles, and blood pressure reduction .

Q: What are the main clinical trials investigating Tirzepatide?

A: Key clinical trials include the SURMOUNT program for obesity management , the SURPASS program for type 2 diabetes, the TIRTLE1 trial for type 1 diabetes , the ongoing SURPASS-T1D-1 Phase 3 trial for type 1 diabetes , SURMOUNT-OSA for sleep apnea, SUMMIT for heart failure, and SYNERGY-NASH for metabolic-associated fatty liver disease .

Q: Do you offer bulk quantities of Tirzepatide for institutional research?

A: Yes. We accommodate bulk orders for research institutions. Contact our team at sales@eupeptidelap.co.uk for volume pricing, custom requirements, and supply agreements for ongoing research programs.

Advance Your Research with Tirzepatide 40mg (R&D Only)

eupeptidelap.co.uk is your trusted source for Tirzepatide 40mg (R&D Only) , the premium choice for researchers investigating metabolic disorders, obesity, diabetes, cardiovascular health, and neuroprotection. As the first-in-class dual GIP/GLP-1 receptor agonist, Tirzepatide represents a revolutionary tool for exploring the synergistic actions of incretin pathways and their broad therapeutic potential across multiple disease states. ...........................................

Whether you are exploring weight loss mechanisms, designing diabetes studies, investigating cardiovascular protection, or researching neuroprotective strategies, our rigorously tested compound provides the quality and consistency your work demands. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Order today and experience the eupeptidelap.co.uk difference – premium quality, rapid 48-hour delivery across the EU and UK, and expert support for the European research community.

change management

Cardarine GW-501516

CJC 1295 with DAC 5mg

Epithalon 10mg

GHK-Cu – 50mg – Research Spray Kit

HCG Peptide

Tirzepatide 40mg (R&D Only)